Sector News

Sanofi starts on viral vector facility as its R&D focus shifts to gene therapies

October 23, 2019
Life sciences

Sanofi is playing catch-up in gene therapy, but new CEO Paul Hudson is taking quick steps to close the gap. A reorganization of the R&D unit is intended to pivot the drugmaker toward immuno-oncology drugs and gene therapies.

And to hasten the transition, the company is retrofitting a vaccine plant in France into a gene therapy manufacturing operation.

A spokesman Monday confirmed Sanofi is preparing teams at its Lyon-Gerland site to work on vector-based gene therapies. Hudson spoke about the project in an interview with BioPharma Dive. The drugmaker expects the facility to be operational a year from now.

Sanofi has invested about €25 million in the Lyon-Gerland site over the last five years. In 2013, the drugmaker struck a deal with France’s Transgene to share the cost of a €10 million facility there to manufacture Transgene’s immuno-oncology therapies.

The Lyon vaccine facility is being retrofitted even as Sanofi this summer reworked its gene therapy partnership with Voyager Therapeutics. Sanofi dumped two programs it has started with Voyager, and now the two will develop adeno-associated virus capsids —the protein shells of the virus—for the delivery of gene therapies. Sanofi gets the exclusive option to use these capsids to deliver treatments for up to two non-CNS diseases.

The project also comes as Sanofi has been upgrading other parts of its manufacturing network for the future. Last week, it opened a new biologics plant in Massachusetts that it considers its prototype plant of the future. In the digitally enabled manufacturing facility, all manufacturing stages are controlled through analytical processes that are forecast to avoid variations.

Plant operators also have access to data analytics or augmented reality solutions that can help them make real-time decisions and adjustments. He said the remade plant is 80 times more productive while also reducing energy use and emissions by 80%.

As for gene therapy production, Sanofi is following other companies such bluebird bio and Gilead’s Kite Pharma in building viral vector manufacturing facilities to serve their gene therapy or CAR-T development programs, which are much further along than Sanofi’s.

By Eric Palmer

Source: Fierce Pharma

1 response to “Sanofi starts on viral vector facility as its R&D focus shifts to gene therapies

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

January 17, 2021

SII expects WHO emergency approval of Covid-19 vaccine soon

Life sciences

The Serum Institute of India (SII) expects to soon receive World Health Organisation (WHO) emergency use authorisation for the Oxford University/AstraZeneca Covid-19 vaccine, produced for mid and low-income countries.

January 17, 2021

Sanofi to acquire clinical-stage biopharma firm Kymab for $1.45bn

Life sciences

According to the deal, Sanofi will gain full global rights to Kymab’s fully human monoclonal antibody, KY1005 that attaches to OX40-Ligand and can potentially treat various immune-mediated diseases and inflammatory ailments.

January 17, 2021

Moderna poaches Amgen vet as CCO, jump-starting commercial team as it rolls out COVID-19 vaccine

Life sciences

Moderna tapped veteran Amgen executive Corinne Le Goff to spearhead that effort as chief commercial officer.

Send this to a friend